Immunity & good health is determined by the collective presence of living symbiotic, and pathogenic microorganisms in the human microbiome system. Throughout the life cycle age accordingly, bacterial community & its characteristics vary.
Nasal cavity mutualistic bacteria compete for space, and nutrients & produce toxic materials, helping repress pathogenic bacteria and inhibit or kill them. Nasal cavity dysbiosis leads to opportunistic pathogenic bacteria presence, spread in the respiratory tract & the development of allergic rhinitis (AR), chronic rhinosinusitis (CRS), acute respiratory tract infections (ARTI), otitis media (OM), and asthma.
CRS
Instigates disease progression, nasal polyps’ development, chronic symptoms, and sinus cavity inflammatory response. The prevalent presence of Coagulase-negative Staphylococcus, Pseudomonas aeruginosa, and S. aureus influence & modulate the immune response.
Determines asthma onset, advancement, acuteness, metagenomic inference & bacterial glycerolipid metabolism and increase in Prevotella buccalis, Gardnerella vaginalis, P. buccalis, G. vaginalis, Dialister invisus, and Alkanindiges hongkongensis species. Asymptomatic expansion of Streptococcus affects the future possibility, danger & later episodes of asthma and its inflammation symptoms.
In asthma-affected children, Moraxella, Staphylococcus, Corynebacterium, Haemophilus, Fusobacterium, Prevotella, and Dolosigranulum dominate the nasal microbiome environment.
Affects the immune response modulation, pathophysiology & AR growth. In seasonal allergic rhinitis (SAR) patients, pollination season spikes symptoms, nasal eosinophils levels & middle meatus bacterial biodiversity.
Controls host’s susceptibility, influenza-specific immunoglobulin A antibody production disparity, taxa richness rise & the surge of Streptococcus pneumoniae, S. aureus, Phyllobacterium, Moraxella, Staphylococcus, Corynebacterium, and Dolosigranulum in the nasal carriage.
Concomitantly S. pneumoniae transmission increases shooting up protease secretion, activates viral hemagglutinins and modulates the innate immune response. Facilitates influenza, A virus (adenovirus, or rhinovirus) infection & associated respiratory virus infection, S. pneumoniae elevation & invasive pneumococcal pneumonia risk.
Regulates Moraxella, Streptococcus, and Pasteurella spp migration from the middle ear to the nose microbiome & leading to OM. S. pneumoniae, Haemophilus, Actinomyces, Rothia, Neisseria, and Veillonella increase in OM-affected children. OM acute episodes escalate abundant increase of otopathogen genera and decrease in Pseudomonas, Myroides, Yersinia, and Sphingomonas.
The nasal passage is colonized with a diverse range of bacteria, fungi, and viruses and it is the first contact point to the external environment exposure. The nasal microbiota profile positively correlates with amplified immune response. Further research is required to reinforce the promising role of probiotic intervention in the supplementary treatment of nasal dysbiosis-connected respiratory infections.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Relationship-building key to addressing oncologist shortages in rural care
2.
New protein target discovered for childhood medulloblastomas
3.
Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL
4.
Papillary thyroid cancer: New markers offer hope for tailored treatment
5.
Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal
1.
Precision Oncology: Tailoring Cancer Treatment for the Individual
2.
Genetic Screening: A Game Changer in Cancer Prevention
3.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
4.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
5.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation